Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
25 Arthritis Trials near Cincinnati, OH
Power is an online platform that helps thousands of Arthritis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerUstekinumab/Guselkumab for Juvenile Psoriatic Arthritis
Cincinnati, Ohio
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Enthesitis-related Arthritis, Tuberculosis, Others
Must Be Taking:Methotrexate, Sulfasalazine
48 Participants Needed
Deucravacitinib for Psoriatic Arthritis
Cincinnati, Ohio
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Other JIA, Uveitis, Others
60 Participants Needed
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Cincinnati, Ohio
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Cancer, Serious Infection, Tuberculosis, Others
Must Be Taking:DMARDs
2600 Participants Needed
Upadacitinib for Juvenile Arthritis
Cincinnati, Ohio
This trial is testing a medication called upadacitinib in children with a type of arthritis that affects many joints. The study aims to see how the drug behaves in their bodies, how safe it is, and how well they can tolerate it. Upadacitinib works by reducing inflammation and pain by blocking certain enzymes in the body. It has been approved for treating rheumatoid arthritis in adults.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:2 - 17
Key Eligibility Criteria
Disqualifiers:Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Must Be Taking:Methotrexate, Glucocorticosteroids
122 Participants Needed
ZILRETTA for Shoulder Osteoarthritis
Cincinnati, Ohio
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo
Secondary Objective:
* To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo
* To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo and TCA-IR
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 80
Key Eligibility Criteria
Disqualifiers:Symptomatic Arthritis, Rotator Cuff Pathology, Chronic Shoulder Pain, Others
Must Not Be Taking:Opioids, Analgesics, THC/CBD, SSRIs/SNRIs
250 Participants Needed
Secukinumab for Giant Cell Arteritis and Polymyalgia Rheumatica
Cincinnati, Ohio
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics \[PK\]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:50 - 100
Key Eligibility Criteria
Disqualifiers:Not Listed
65 Participants Needed
TNFi Therapy Strategies for Juvenile Spondyloarthritis
Cincinnati, Ohio
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 21
Key Eligibility Criteria
Disqualifiers:Inflammatory Bowel Disease, Uncontrolled Uveitis, Psoriasis, Others
Must Be Taking:TNFi Therapies
198 Participants Needed
Abatacept Injection for Juvenile Idiopathic Arthritis
Cincinnati, Ohio
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:2 - 16
Key Eligibility Criteria
Disqualifiers:Not Listed
121 Participants Needed
Tofacitinib for Juvenile Arthritis
Cincinnati, Ohio
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:2 - 18
Key Eligibility Criteria
Disqualifiers:Not Listed
281 Participants Needed
Ziltivekimab for Cardiovascular Disease
Cincinnati, Ohio
This trial is testing whether ziltivekimab can lower the risk of heart attacks and strokes in people with heart disease, kidney disease, and inflammation. Participants will inject the medicine regularly. The study aims to see if reducing inflammation can help prevent serious heart problems.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Active Infection, Recent Heart Attack, Recent Stroke, Others
6200 Participants Needed
Knee Replacement for Osteoarthritis
Cincinnati, Ohio
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona fixed bearing knee implants used in total knee arthroplasty. The assessment will include implant survivorship and clinical performance.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Infection, Osteoporosis, Neuromuscular Disease, Others
737 Participants Needed
Fitness Training for Juvenile Arthritis
Cincinnati, Ohio
This study evaluates the feasibility of the Fitness Integrative Training program for Teens (FIT Teens 2), a combined cognitive behavioral therapy and neuromuscular exercise training program in patients with pediatric rheumatic diseases and/or joint hypermobility.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 19
Key Eligibility Criteria
Disqualifiers:Major Psychiatric Diagnoses, Developmental Delay, Others
20 Participants Needed
Adalimumab Discontinuation for Uveitis
Cincinnati, Ohio
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).
Trial Details
Trial Status:Active Not Recruiting
Age:2+
Key Eligibility Criteria
Disqualifiers:Not Listed
87 Participants Needed
Emapalumab for MAS in Still's Disease or Lupus
Cincinnati, Ohio
This trial is testing emapalumab, a medication that helps control an overactive immune system, in children and adults with certain immune conditions who haven't responded to high-dose steroids. The goal is to see if it is safe and effective in reducing excessive inflammation. Emapalumab is a monoclonal antibody that targets interferon-γ and was first approved for treating primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive disease.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 80
Key Eligibility Criteria
Disqualifiers:Primary HLH, Malignancy, Active Infections, Others
Must Be Taking:Glucocorticoids
41 Participants Needed
BMS-986278 for Pulmonary Fibrosis
Cincinnati, Ohio
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:21+
Key Eligibility Criteria
Disqualifiers:Idiopathic Pulmonary Fibrosis, Stroke, Heart Failure, Current Malignancy, Others
Must Not Be Taking:Systemic Corticosteroids
1092 Participants Needed
Guselkumab vs Golimumab for Psoriatic Arthritis
Blue Ash, Ohio
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Heart Failure, Others
Must Be Taking:TNFi, OSM/csDMARDs
150 Participants Needed
Risankizumab for Psoriatic Arthritis
Blue Ash, Ohio
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Hypersensitivity To Risankizumab, Others
Must Not Be Taking:Biologic Agents
964 Participants Needed
Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis
Liberty Township, Ohio
This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:HIV, Heart Failure, Hepatitis, Others
Must Be Taking:TNFi-biologic
924 Participants Needed
Tildrakizumab SC Injection for Psoriatic Arthritis
Cincinnati, Ohio
An open label phase 3 study
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Others
650 Participants Needed
Baricitinib for Rheumatoid Arthritis
Cincinnati, Ohio
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Cancer, Active Tuberculosis, Serious Infection, Others
Must Be Taking:DMARDs
1300 Participants Needed
Why Other Patients Applied
"I’m allergic to so many standard arthritis drugs, so I've been researching some of the newest ones still in the research phase. I'm hoping to find out if I'd be a good match—it would be great to find something that works (and, if not, at least contribute to the cause)."
TJ
Arthritis PatientAge: 79
"I’ve tried several meds without too much relief. Injections only work on my right knee but not much on the left knee. My pain is nearly unbearable at this point. Hoping to learn about what promising drugs exist in trials."
YV
Arthritis PatientAge: 61
"I have been struggling with severe knee pain since my service in the military. I am only 52! I miss doing the things I used to do."
NA
Arthritis PatientAge: 55
"I've been 17+ years in pain with bilateral osteoarthritis. PRP and HA injections have not helped. Physical therapy has helped only to a certain degree. I'm looking for new treatment options before considering replacement. "
RH
Arthritis PatientAge: 39
"I am an active athlete who is not ready or willing to stop my activities because of knee pain at 42. I have tried cortisone shots and found they only temporary mask the issue, or even cause more problems later. That's why I started researching medical studies."
GM
Arthritis PatientAge: 44
AR882 for Gout
Mason, Ohio
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Malignancy, Pregnant, Kidney Stones, Others
750 Participants Needed
Bimekizumab for Psoriatic Arthritis
Middletown, Ohio
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Active Infection, Tuberculosis, Rheumatoid Arthritis, Others
Must Be Taking:CsDMARDs
550 Participants Needed
Guselkumab for Psoriatic Arthritis
Springboro, Ohio
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Rheumatoid Arthritis, Lupus, Others
Must Not Be Taking:Biologics, JAK Inhibitors
1054 Participants Needed
Upadacitinib for Rheumatoid Arthritis
Dayton, Ohio
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Adalimumab, Inadequate BDMARD Response, Others
Must Be Taking:Methotrexate
1629 Participants Needed
AR882 for Gout
Dayton, Ohio
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Malignancy, Pregnant, Kidney Stones, Others
750 Participants Needed
Know someone looking for new options?
Spread the word